Isomorphic Labs secures $2.1 Billion funding to scale its AI drug design engine

Isomorphic Labs, an AI-driven drug design and development company, has successfully raised $2.1 billion in a Series B funding round, announced on May 12, 2026. The investment round was led by Thrive Capital and saw participation from several notable investors, including Alphabet, GV, MGX, Temasek, CapitalG, and the UK Sovereign AI Fund. This substantial capital infusion aims to enhance Isomorphic Labs' AI drug design capabilities and support its global expansion efforts.

The funding will primarily be utilized to accelerate the development of Isomorphic Labs' AI drug design engine, known as IsoDDE, and to expand its pipeline of therapeutic programs. The company has established itself as a leader in the application of artificial intelligence to drug discovery, leveraging proprietary models that integrate scientific and engineering disciplines. This investment will enable Isomorphic Labs to hire top-tier talent in AI, engineering, and clinical research, essential for addressing complex biological and medical challenges.

Isomorphic Labs was founded in 2021 and has quickly positioned itself at the forefront of AI-driven drug discovery. The company has built a strong portfolio of strategic partnerships with major pharmaceutical players, including Novartis, Lilly, and Johnson & Johnson. These collaborations not only validate Isomorphic's innovative approach but also highlight the potential of its technology to deliver significant advancements in drug design and development.

The broader market for AI in healthcare is rapidly evolving, with increasing recognition of the transformative potential of these technologies. As Isomorphic Labs continues to refine its AI drug design engine and scale its operations, the implications for the pharmaceutical industry could be profound. The ability to streamline drug discovery processes and improve the accuracy of predictive models may lead to faster development of new therapies, ultimately addressing the global burden of disease more effectively.

In summary, the $2.1 billion funding round for Isomorphic Labs marks a significant milestone in the intersection of artificial intelligence and drug discovery. With the backing of prominent investors and a clear strategic vision, Isomorphic Labs is poised to redefine the future of medicine, driving innovation and efficiency in the pharmaceutical sector. The ongoing advancements in AI technology will likely continue to shape the landscape of drug development, presenting opportunities for both investors and healthcare providers alike.